TY - JOUR
T1 - Lung cancer biomarkers
T2 - present status and future developments.
AU - Cagle, Philip T.
AU - Allen, Timothy Craig
AU - Olsen, Randall J.
PY - 2013/9
Y1 - 2013/9
N2 - The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.
AB - The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.
UR - http://www.scopus.com/inward/record.url?scp=84887556493&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887556493&partnerID=8YFLogxK
U2 - 10.5858/arpa.2013-0319-CR
DO - 10.5858/arpa.2013-0319-CR
M3 - Review article
C2 - 23991729
AN - SCOPUS:84887556493
SN - 1574-7891
VL - 137
SP - 1191
EP - 1198
JO - Molecular Oncology
JF - Molecular Oncology
IS - 9
ER -